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ABSTRACT
In deceased donor kidney transplantation, the decision to accept or decline an offer relies
on a clinicians intuition and ability to digest complex information in order to maximize
patient survival. Risks affecting patient survival post-KT must be balanced with the risks
of remaining on the waitlist. These risks include mortality, graft failure, and becoming too
sick to transplant. The allocation system today takes these risk into account by way of
the KDPI and EPTS scores. While these scores are discriminative of patient survival they
were built with an assumption of independence between risks and very few donor-recipient
variables. Deep learning survival analysis can effectively handle competing risks and learn
complex relationships between many more donor-recipient variables. We used DeepHit to
assess the risk benefit associated with accepting a kidney offer or remaining on the waitlist.
Our models achieved comparable, if not better performance in certain tasks, with other
high performing models in the literature and revealed that decoupling competing risks led
to increased clinical information gain. We show that comprehensively modeling competing
risks using machine learning can achieve more granular, meaningful clinical risk analysis
enabling more effective decision making in deceased donor kidney transplantation.
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CHAPTER 1: INTRODUCTION
Organ transplantation is a complex process requiring effective coordination and commu-
nication amongst a highly distributed network of providers within a short window of time in
order for a successful transplantation to occur (Figure 1.1). Over 80% of patients awaiting
organ transplants are waiting for a kidney. Kidney transplantation (KT) is a clinically effec-
tive and cost-effective treatment for patients suffering from end-stage renal disease (ESRD)
[1, 2, 3]. More than $34B of the annual Medicare budget is devoted to paying for the
treatment of patients who require dialysis while awaiting a KT. Transplanting this group
could save $100,000 per year per patient amounting to $46.8B annually [4] and a gain of
6.7 discounted quality-adjusted life years (QALYs) for every dialysis patient who receives a
kidney. Despite the obvious clinical and cost-effectiveness advantages of kidney transplan-
tation, there has been a decades-long rise in the kidney discard rate from 5.1% in 1988 to
19.2% in 2015 [5]. Studies have shown that a portion of these kidney could have provided
a survival benefit to waitlisted patients and that behavioral factors, such as increased risk
aversion, could play a part in the rising discard rate [5, 6, 7]. On the behavioral side, there is
also a demonstrated reduction in acceptance of kidneys on the weekends v.s. the weekdays
[8]. Ultimately, a kidney accept or decline decision comes down to a complex estimation
of risk done by sole physicians relying on experience and intuition. Clinical decision sup-
port (CDS) may significantly increase access, increase quality, and reduce the cost of kidney
transplantation.
Figure 1.1: Complex process of organ allocation and procurement.
Similar to reasoning done by Wey et al.[9], the ultimate question is: does this offer max-
1
imize graft and patient survival for the recipient? If it does, the offer should of course be
accepted. It’s important to note that there isn’t one single donor profile that maximizes
those two variables for every recipient. Aside from the baseline compatibility requirements
(e.g. size, blood type, and other medical factors), other factors such as geography and local
organ supply come into play. Therefore, an accept or decline decision comes down to 3
factors:
1. Survival should the offer be accepted.
2. Survival should the offer be declined and the patient remain on the waiting list (WL).
3. Survival opportunity sometime in the future in the form of a better offer.
This thesis attempts to robustly addresses factors 1 and 2 using state of the art deep learning
techniques in survival analysis with competing risk. Factor 3 is left for future work and will
build on work done by Wey et al. and Bertsimas et al [9, 10].
The rest of the thesis is organized as follows. Chapter 2 dives into related work and
provides a good overview on survival analysis within kidney transplantation. Chapter 3
explains our approach and describes the Scientific Registry of Transplant Recipients (SRTR)
data set we used. Chapter 4 shows our results and attempts to demonstrate the clinical
validity using CDS at the time of offer. Chapter 5 concludes this thesis and ventures into
future work.
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CHAPTER 2: RELATED WORK
Kidney transplantation as explained in the introduction is a very complex system involving
multiple patients vying for a perfectly matched kidney. There are multiple data sources in
play from the allocation system, the individual patients, and the organ procurement system.
Machine learning techniques offer a more efficient way at processing this large amount of
data and the complex interactions between them with the ultimate goal of reducing waste,
transplanting more patients, and maximizing patient survival. The following sections will
describe the following work in relation to our work: (1) how survival analysis is used in
kidney transplantation, (2) current allocation policies using machine learning, (3) the SRTR
efforts in providing analytic tools for patient and physician use, and (4) previous applications
of machine learning for kidney offer evaluation.
2.1 SURVIVAL ANALYSIS IN KIDNEY TRANSPLANTATION
Survival analysis is used extensively in medicine to analyze time-to-event data such as from
a cohort study or clinical trial. In the case of post-KT survival, two events are prevalent:
death and graft failure. Survival analysis allows one to find casual relationships, predict
temporal risk, or analyze non-parametric based patient survival. Additionally, this type of
analysis allows for censoring of individuals. For example, if in the study period a patient did
not exhibit any outcome of interest they are considered to be right-censored. Left-censorship
occurs when a birth event is not seen.
Common methods used in KT are the non-parametric Kaplan-Meier (KM) method [11],
the Cox proportional hazard model [12], and the Fine and Gray model [13]. The KM method
estimates the probability of survival across a period of time using only time and censoring
data. A Cox model would be used in evaluating casual relationships between predictive
covariates and survival. It consists of a baseline hazard which represents the hazard of an
individual with baseline covariates. This baseline is affected by each covariate, therefore
allowing one to study the effect of individual covariates on survival. The Fine and Gray
model is a more advanced technique providing sub-distribution hazards in the presence
of competing risks. In addition the cumulative incidence function (CIF) was developed
to overcome some of the shortcomings of the KM method [14]. It effectively shows the
cumulative probability over time due to an event in the presence of competing events.
A proper example of survival analysis in kidney transplant was done by Sapir-Pichhadze
et al. in their study of WL kidney transplant candidates [15] with competing events (death,
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transplant or removal from WL for any other reason). They compared competing event
analysis using a cause-specific Cox model with the Fine and Gray model. Interestingly, they
demonstrated that appropriately handling competing risks leads to more refined predictions
in the presence of competing risks. This thesis takes care to handle competing risks not only
for WL outcomes but also in post-KT outcomes.
2.2 ALLOCATION POLICIES
The US allocation system for kidney’s recently began factoring in survival benefit in
2015. Survival benefit is considered by using a candidates estimated post transplant survival
(EPTS) and a donors kidney donor profile index (KDPI). These scores were developed using
Cox regression. The EPTS score considers the following four factors: candidate time on
dialysis, current diagnosis of diabetes, prior solid organ transplants, and candidate age.1
The KDPI score considers a donors age, ethnicity, creatinine levels, history of hypertension,
history of diabetes, cause of death, height, weight, donor type (deceased or living), and HCV
status.2 Lower KDPI scores have been shown to be associated with higher rates of survival.
For example, The Organ Procurement and Transplantation Network states that the half-life
of a graft from a donor with KDPI of 0%-20% is expected to be around 11 years post-KT
and decreases to about 9 and 5.5 years with KDPI’s of 21%-85% and 86%+, respectively
[16]. Similar expectations of survival with EPTS have been found. To maximize survival
benefit good recipients are matched with good donors using KDPI and EPTS. Candidates
with EPTS scores of 20% or less are matched with kidneys from donors with KDPI scores
of 20% or less before candidates at local, regional, and national levels of distribution [17].
KDPI and EPTS represent proper first steps towards a more efficient allocation system.
However, more robust machine learning methods have shown better discriminative perfor-
mance [18]. It is important to note that the variables used in these metrics are more or less
guaranteed to be on hand at the time of transplant. To maintain usability in practice these
variables should be included along with other ubiquitous variables.
1https://optn.transplant.hrsa.gov/resources/allocation-calculators/epts-calculator/
2https://optn.transplant.hrsa.gov/resources/allocation-calculators/kdpi-calculator/
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2.3 SRTR ANALYSIS TOOLS
The SRTR currently publishes risk adjustment models models for both post-KT outcomes
and WL outcomes among others.3,4 For Post-KT outcomes they include 1 and 3 year
graft and patient survival. For WL outcomes they include transplant rate, deceased donor
transplant rate and WL mortality. By building seperate models for every event they are
employing cause-specific Cox and Poisson survival models. This approach has been found
to be the preferred method for evaluating causal relationships in the presence of competing
risk, but not for predicting the actual risk of the outcome [15]. Indeed the SRTR website
only lists model coefficients allowing a transplant professional to examine the effect of a
predictive variable on the outcome of interest; leaving room for more patient-specific risk
models to be developed. Additionally, usability in practice is limited due to the amount of
manual processing and interpretation needed from a users perspective.
2.4 MACHINE LEARNING FOR KIDNEY OFFER EVALUATION
In kidney transplantation alone, machine learning has been used to predict chronic allo-
graft rejection, delayed graft function (DGF), and allograft survival [19, 20, 21, 22, 23].
Decruyenaere et al. [19] compared logistic regression with more advanced machine learning
methods for predicting DGF after kidney transplantation. DGF means a patient must go
back on dialysis within the first week after transplantation. They concluded that a linear
SVM is most appropriate for this task, not finding any significant performance boost using
random forests (RF), stochastic gradient boosting (SGB), and decision trees (DT) among
others. However, their dataset was relatively small (under 500 samples) and they only had
access to 55 total variables, 20 of which were used in training. Furthermore, the DGF
outcome was only observed in 12.5% of patients.
Krikov et al. [20] built tree-based models to predict the probabiliy of kidney allograft
survival at 1, 3, 5, 7, and 10 years post-KT. They had relatively good success with high AUC
scores of 0.63, 0.64, 0.71, 0.82 and 0.90 for their respective prediction timelines. However,
their models converted the outcome to a binary indicator and potentially missed information
relating to competing outcomes such as death without graft failure and graft failure without
death.
Li et al. [23] used a bayesian network to predict graft rejection and survival period. Their
graft rejection model performed relatively well with 97.8% accuracy, however accuracy was
3https://www.srtr.org/reports-tools/risk-adjustment-models-posttransplant-outcomes/
4https://www.srtr.org/reports-tools/risk-adjustment-models-waiting-list/
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68.2% for the survival period task. Their results indicated that a bayesian network was ill
suited for the former task.
These studies only looked at post-KT events, effectively only addressing factor 1. Studies
that included WL survival have looked at predicting WL mortality and other events pertain-
ing to removal from the WL [9, 18]. Both of these studies addressed factor 1 & 2 and used
survival analysis techniques. Wey et al. also addressed factor 3 by incorporating survival
estimates after declining an offer and receiving a subsequent living or decreased donor offer.
Neither of these studies utilized deep learning to handle survival analysis in the presence of
competing risks nor effectively handled bias in their performance evaluation [24].
6
CHAPTER 3: APPROACH
3.1 DATASET
There are multiple large, comprehensive national kidney transplantation datasets avail-
able [25]. Data curated by the Organ Procurement and Transplantation Network (OPTN),
described in Table 3.1, serves as the basis for the most widely used datasets including the
United Network for Organ Sharing (UNOS), the Scientific Registry of Transplant Recipi-
ents (SRTR), and the United States Renal Data System (USRDS) datasets. We used data
obtained from the SRTR. Additional data for the ascertainment of graft failure and death
came from the Centers for Medicare and Medicaid Services (CMS); cancer ascertainment
from the Surveillance, Epidemiology, and End Results program (SEER); and additional
death ascertainment from the National Death Index (NDI).
Table 3.1: The OPTN collects most data via one of three forms described in the table. These
forms provide the basis for many of the larger datasets used by researchers today.
OPTN Form Types of Data Collected
Transplant Candidate Registration (TCR)
Candidate demographic data, clinical infor-
mation and history, organ-specific informa-
tion at the time of listing.
Transplant Recipient Registration (TRR)
Pre-transplant clinical data, infectious dis-
ease status, data on the transplant proce-
dure, post-transplant clinical data, infor-
mation on immunosuppressive medications
from the initial transplant admission.
Transplant Recipient Follow-up (TRF)
Vital status, cause of death if applicable,
graft status patient education and employ-
ment status, and clinical information at
each visit following a transplant.
Deceased Donor Registration (DDR) and
Living Donor Registration (LDR)
Donor demographics, comorbidities, infec-
tious disease status, and cause of death (for
deceased donors) or postoperative clinical
information (for live donors) at the time of
organ donation.
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3.2 STUDY POPULATION
The recipient cohort included all adult (aged 18 and over) KT recipients between Jan-
uary 1, 2005 and December 31, 2016 (n = 114,261). Multi-organ recipients were excluded.
Patients who had received a prior transplant and only deceased donor KT recipients were
included. The waiting list cohort included all adult patients who were activated on the KT
waiting list between January 1, 2005 and December 31, 2016 (n = 217,278). Multi-organ
candidates were excluded. If a candidate didn’t have a removal date they were excluded and
multiple registrations were consolidated.
3.3 TRANSPLANT SURVIVAL
Transplant survival was defined as the time from KT to death or graft rejection, censoring
for the end of the study. We treated graft failure as a competing event to death and noted the
first event that occurred as the primary outcome for that patient. To maintain usability in
practice we limited the features to those used by the SRTR postransplant models (described
in related work) and 12 other variables found to influence post-KT survival in the previous
studies. A sample was excluded if it was missing 20% or more of it’s variables. A total of 25
features were utilized. Missing continuous variables were replaced with their median, while
missing categorical variables were labelled as missing. We used one-hot encoding and all
variables were normalized using the standard score.
3.4 WAITLIST SURVIVAL
Waitlist (WL) survival was defined as the time from activation on the waitlist to 3 com-
peting risks and censoring defined as:
1. death,
2. KT,
3. too sick to transplant,
4. or censorship for the end of the study or removal from the waitlist for any other reason.
Only features that had at least 90% coverage were kept, unless those features were deemed
clinically relevant in previous literature and in the SRTR models. Missing continuous vari-
ables were replaced with their median, while missing categorical variables were labelled as
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missing. Bae et al. showed that the inclusion of time-varying variables that affect survival,
including those used in this study, are sufficient to assume that the association between
these features and survival are consistent regardless of when an offer is received [18]. We
used one-hot encoding and all variables were normalized using the standard score.
3.5 DEEPHIT
Figure 3.1: DeepHit Architecture.
We use a modified version of DeepHit developed by Lee et al. [26] based on code avail-
able on github.1 This deep learning architecture (Figure 3.1) has been shown to enhance
performance in the presence of competing risks. The first network is shared between events
and is followed by cause-specific sub-networks for each competing event. Two loss functions
(Ltotal = L1 + L2) are utilized:
L1 = −
N∑
i=1
[1(k(i) 6= ∅) · log(y(i)
k(i),s(i)
) + 1(k(i) 6= ∅) · log(1−
K∑
k=1
Fˆk(s
(i)|x(i)))] (3.1)
L2 =
K∑
k=1
αk ·
∑
i 6=j
Ak,i,j · η(Fˆk(s(i)|x(i)), Fˆk(s(i)|x(j))) (3.2)
Where,
• Fˆk∗ is the estimated CIF for event k∗ at time s∗, Fˆk∗(s∗|x∗) =
∑s∗
m=0 y
∗
k,m,
1https://github.com/chl8856/DeepHit
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• Ak,i,j represents acceptable pairs (i,j) that experience event k at a different time and
can thus be compared, Ak,i,j , 1(k(i) = k, s(i) < s(j)),
• αk is chosen to trade off ranking losses of the k-th event,
• η(x, y) is a convex loss function, η(x, y) = exp(−(x− y)
σ
).
L1 is the log-likelihood of the joint distribution of the first hitting time and event that takes
into account censoring. L2 learns the general representation for the joint distribution of the
first hitting time and events using ranking loss with cause-specific CIFs helping the network
to perform better on time intervals where there are a large number of death events.
3.6 MEASURES OF PERFORMANCE & CALIBRATION
We used a time dependent measure of performance based on the widely used Concordance
index (c-index) in survival analysis. The ordinary c-index [27] represents the fraction of all
patients that were ordered correctly out of all patients that could of been ordered. It doesn’t
take into account the change in risk over time and is biased if the censoring distribution is
influenced by the input variables [24]. For example, in the case of KT-survival the chance of
censoring over the study period is dependent on medical factors at the time of transplant,
such as KDPI and EPTS. In essence, a more risky transplant corresponds to a higher chance
of reduced survival and thus lower chance of censorship in any survival study. The time-
dependent c-index (C(t)) adjusted for censoring [28] and is defined by:
C(t) = P(R(t|xi) > R(t|xj)|∆i = 1, Ti ≤ t, Ti < Tj). (3.3)
To measure calibration we used the Brier Score (BS) [28]:
BS(t) = E[1(Ti ≤ t)−R(t|xi))2]. (3.4)
3.7 RISK BENEFIT
Risk benefit of KT compared to staying on the WL was calculated by taking the difference
between risks. Only the following risk differences were calculated:
1. KT death vs WL death,
2. KT death vs becoming too sick,
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3. KT graft failure vs WL death,
4. KT graft failure vs becoming too sick.
The ultimate trade-off comes down to KT death vs WL death. The other measures, represent
more granular trade-offs. For example, suppose a patient has a lower risk of death by taking
a KT but a higher risk compared to becoming too sick. In this case, the patient could stay
on the WL and wait for a better kidney since their chances of being removed from the WL
are lower than death post-KT. This is one of the benefits of modeling competing risks.
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CHAPTER 4: RESULTS
4.1 POPULATION CHARACTERISTICS
In the recipient cohort (n = 114,261), 33.9% were African American, the median age was
54 years old, 27.3% had diabetes as the primary diagnosis, median time on dialysis was 3.7
years, and 14.5% had previous transplants. The recipients received organs from donors of
whom 14.3% were African American, the median age was 41, 7.2% had a history of diabetes,
27.8% had a history of hypertension and 33.2% donated after cerebrovascular/stroke death.
The median KDPI and EPTS was 44 and 41, respectively. In the candidate group (n =
217,278), the median age was 55, 31.6% were African American, they had a little bit higher
rates of hypertension (23.9%) and diabetes (36.1%) compared to those in the candidate
group, 26.1% had a functional status of 80%, and the median EPTS score was 36 (Table
4.1).
Table 4.1: Population Characteristics.
Recipient Cohort(n = 114,261) Candidate Cohort(n = 217,278)
Recipient/Candidate Factors
Age at transplant, y 54 (44-63)
Age at waitlisting, y 55 (45-63)
Race, %
White 41.2% 44.9%
African American 33.9% 31.6%
Hispanic/Latino 16.3% 16.5%
Other/multiracial 8.6% 7.0%
Primary Diagnosis, %
Diabetes 27.3% 36.1%
Hypertension 25.7% 23.9%
Glomerular 11.4% 8.6%
Cystic 7.6% 6.2%
Congenital 0.7% 0.5%
Other 26.8% 24.0%
Missing 0.5% 0.6%
Total Albumin, g/dL 3.9 (3.6-4.2) 3.9 (3.6-4.2)
Education Level, %
High School 42.3% 41.6%
College/Technical School 22.7% 22.9%
Undergraduate Degree 13.9% 14.1%
Unknown 8.4% 7.5%
Peripheral Vascular Disease 6.5% 7.5%
Time on Dialysis, y 3.7 (2.0-5.9) 0.0 (0.0-1.2)
Primary Insurance, %
Medicare FFS 51.5% 37.6%
Private 22.2% 37%
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Table 4.1 Continued
Medicare & Choice 19.4% 14.9%
EPTS, % 41 (18-71) 36 (17-58)
Previous Transplant, % 14.5%
Time on the Waitlist, y 2.1 (0.8-3.6)
Cold Ischemic Time, hrs 16.5 (11.4-22.3)
Functional Status, %
80%1 26.1%
90%2 23.5%
70%3 19.4%
100%4 12.1%
Donor Factors
Age, y 41 (26-52)
Race, %
White 82.2%
African American 14.3%
Other/Multiracial 3.5%
Weight, kg 78.8 (66-93)
Height, cm 171.0 (163.0-179.0)
Diabetes, % 7.2%
Hypertension, % 27.8%
Serum Creatinine, mg/dL 0.95 (0.7-1.3)
Hepatitis C virus infection, % 2.7%
Cause of Death, %
Head Trauma 36.0%
Cerebrovascular/Stroke 33.2%
Anoxia 27.5%
Shared Transplant, % 25.8%
KDPI, % 44 (21-68)
Table 4.2: Competing Risks Summary.
Percent Event/Censoring Time (y)
Post-KT Survival
Censored 73.2% 4.5 (2.0-7.7)
Graft Failure 13.9% 2.4 (0.5-4.8)
Death 12.8% 3.0 (0.9-5.4)
WL Survival
KT 50.0% 2.6 (1.2-4.4)
Death 20.1% 2.5 (1.2-4.2)
Censored 17.1% 3.1 (1.7-5.1)
Too sick to transplant 12.7% 3.4 (1.9-5.3)
Values are median(IQR) for event/censoring time.
In the recipient cohort, 13.9% experienced graft failure while 12.8% died. The median
1Normal Activity with effort: some symptoms of disease
2Able to carry on normal activity: minor symptoms of disease
3Cares for self: unable to carry on normal activity or active work
4Normal, no complaints, no evidence of disease
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(IQR) times until graft failure or death was 2.4 (0.5-4.8) years and 3.0 (0.9-5.4) years,
respectively. In the candidate cohort, 50.0% of patients received a KT, 20.1% died on
the waiting list, and 12.7% were removed from the waiting list after becoming too sick to
transplant. The median (IQR) times until the events were 2.6 (1.2-4.4) years, 2.5 (1.2-4.2)
years, and 3.4 (1.9-5.3) years, respectively (Table 4.2). Figures 4.1 and 4.2 show the 1-KM
and CIF curves for each event. The CIF for post-kT outcomes was almost equivalent to the
1-KM curve, albeit the 1-KM curve consistently has higher risk. Meanwhile, the CIF for
WL outcomes was drastically more accurate than the 1-KM curve showing the probability
of KT being greater than 3x as likely to occur compared to death or becoming too sick to
transplant. Interestingly, death and graft failure post-KT had relatively equivalent risk.
Figure 4.1: Distribution function 1-KM and cumulative incidence function of competing
events post-KT.
Figure 4.2: Distribution function 1-KM and cumulative incidence function of competing
events on the waiting list.
14
4.2 POST-KT SURVIVAL
For post-KT survival the DeepHit model achieved a 5-year c-cindex of 0.70 and 0.64 for
death and graft failure, respectively. In comparison, KDRI is known to have a c-index of
0.62, while several other methods achieve similar performance to this model going up to
0.724 [29, 30]. LYFTs reported performance for graft survival 0.61 [31]. The 5-year brier
score was 0.46 for both death and graft failure (Figure 4.3).
Figure 4.3: Time dependent C-index and Brier Score for the KT survival model.
The risk of graft failure was slightly greater than death at all time points. 5- and 10-year
risk of death was 11.5% and 13.1%, respectively. While the 5- and 10-year risk of graft failure
was 19.3% and 20.1%, respectively. Interestingly, patients that died had greater accelerated
risk of death at all time points compared to patients that experienced graft failure while
the opposite was observed in patients that experienced graft failure. 5- and 10-year risk of
death was 16.3% and 27.1% for patients that died compared to 11.1% and 18.4% for patients
that experienced graft failure. 5- and 10-year risk for graft failure was 13.1% and 20.6% for
patients that died compared to 15.3% and 22.8% for patients that experienced graft failure
(Figure 4.4).
EPTS showed a strong correlation with 3-, 5-, and 10-year risk of death, while showing
relatively no correlation with 3-, 5- and 10-year risk of graft failure. KDPI on the other
hand showed a stronger correlation with 3-, 5-, and 10-year risk of graft failure compared
to death (Figures 4.5 and 4.6). Clinically this means that EPTS is more indicative of
recipient condition, while KDPI is more indicative of graft condition in the future. This is
consistent with the fact that EPTS and KDPI are derived from recipient and donor variables,
respectively. Patients with low EPTS (≤25th percentile) showed a much lower risk of death
compared to patients with a high EPTS (≥75th percentile). Interestingly, the risk of graft
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Figure 4.4: Median risk for all patients in the test set and for all patients in the test set
seperated by event observed.
Figure 4.5: 3-, 5-, and 10-year post-KT risk and EPTS at the time of KT. Death is shown
on the top row and graft failure on the bottom with their respective years post-KT.
failure was relatively the same with low EPTS patients having marginally higher risk for graft
failure (<2%) from 20 to 90 months post-KT. Patients with low KDPI (≤25th percentile)
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showed a much lower risk for graft failure and death post-KT (Figure 4.7).
Figure 4.6: 3-, 5-, and 10-year post-KT risk and KDPI at the time of KT. Death is shown
on the top row and graft failure on the bottom with their respective years post-KT.
Figure 4.7: Median risk for all patients in the test set seperated by EPTS and KDPI (25th
and 75th percentiles) observed.
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Figure 4.8: EPTS, KDPI and Risk at 3-, 5-, and 10-year post-KT risk for death and graft
failure observed in the test set.
Combining EPTS and KDPI showed a linear trend with risk of death, wherein a low EPTS
recipient receiving a low KDPI kidney showed much lower risk of death at 3-, 5- and 10- years
post-KT, compared to the opposite. At 10-years post-KT the risk difference for death was
up to 30% as KDPI and EPTS increase. The risk of graft failure on the other hand showed a
strong trend with KDPI alone, corroborating with results previously discussed. At 10-years
post-KT the risk difference graft failure was up to 20% as KDPI increased. Interestingly,
very low EPTS (<10% EPTS) recipients were found to have higher risks of graft failure
with KDPI donors up to 75%, however this EPTS score range was outside the IQR and the
support for this edge case is likely very low (Figure 4.8).
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4.3 WAITLIST SURVIVAL
For WL survival the DeepHit model achieved a 3-year c-cindex of 0.75, 0.72, and 0.77
for KT, death, and becoming too sick, respectively. In comparison, the LYFT score has a
reported c-index of 0.68 (0-15 years) [31]. The 3-year brier score was 0.34, 0.39 and 0.46 for
KT, death, and becoming too sick, respectively (Figure 4.9).
Figure 4.9: Time dependent C-index and Brier Score for the WL set.
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Figure 4.10: Median risk for all patients in the test set seperated by event cohort.
Patients that died or became too sick on the WL had greater risk for death or becoming
too sick respectively. Patients that had a KT had a much greater chance of receiving a KT
than any other event. Interestingly, in the near term (<12 months) the risk of death for
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patients that died was greater than KT. On a longer time scale the chance of receiving a
KT is greater than any other event. Clinically it makes sense that if a patient survives long
enough he/she will most likely have a KT. For patients that underwent a KT, the median
risk of KT, death, and becoming too sick was 19.0%, 11.1% and 6.3%, respectively at 2
years, and 32.4%, 19.9%, and 12.2% respectively at 4 years. For patients that died on the
WL, the median risk of KT, death, and becoming too sick was 15.2%, 13.8% and 8.1%,
respectively at 2 years, and 29.0%, 22.4%, and 14.6% respectively at 4 years. For patients
that become to sick to transplant, the median risk of KT, death, and becoming too sick was
14.6%, 12.6% and 9.2%, respectively at 2 years, and 28.2%, 21.2%, and 16.1% respectively
at 4 years (Figure 4.10). Modifying a patient to have a higher EPTS (>80) raised their risk
of death and becoming too sick drastically. Again the pattern of risk of death being greater
than KT in the short term emerges (Figure 4.11).
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Figure 4.11: Risk for a patient that was transplanted with modified EPTS.
4.4 DECISION ANALYSIS
1-, 3-, and 5-year risk benefit of KT for graft failure vs death on the WL showed that
higher EPTS patients benefit the most from a KT while very low EPTS patients can safely
remain on the WL. This is also true in comparing graft failure with becoming too sick to
transplant. The risk benefit at 3-years ranges from -5% to +12.5% for death on WL and
-10% to +10% for becoming too sick to transplant. 1-, 3-, and 5-year risk benefit of KT for
20
death post-KT vs death on the WL showed that essentially every patient would do better
with a KT. This is important because it corroborates the pre-emptive KT strategy put forth
by clinicians, however only 20% of KTs are performed pre-emptively.5 Ultimately, 3-year
risk benefit ranged from 0% to +8% going up to +10% at 5-years post-KT. Even for low
EPTS patients their risk of death is improved with KT, while their risk of graft failure is not,
meaning the patient would improve their survival simply by continually undergoing a KT
each time their graft fails rather than remaining on dialysis. Similar findings between death
post-KT vs becoming too sick were found. although the risk benefits were comparatively
smaller ranging from -6% to +4% at 5 years (Figure 4.12).
5https://www.mayoclinic.org/tests-procedures/pre-emptive-kidney-transplant/pyc-20384830
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Figure 4.12: EPTS, KDPI and risk benefit of KT at 1-, 3-, and 5-years.
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CHAPTER 5: CONCLUSION AND FUTURE WORK
5.1 CLINICAL SIGNIFICANCE
Ultimately, this hypothetical CDS system achieved comparable if not better performance,
while also considering a more robust competing event framework. In particular, the treat-
ment of death and graft failure as competing events proved to capture valuable clinical
information affecting factor 1 (survival with KT). The WL model proved to delineate pa-
tients with higher EPTS scores and patients that died or became to sick on the waitlist,
effectively addressing factor 2 (survival rejecting KT). While this model includes KT as a
WL outcome it doesn’t utilize any location data, other than a candidates permanent state.
To effectively address factor 3 (survival opportunity in the future), more granular data such
as local organ supply and geographical allocation factors are needed. However, it was shown
that for the majority of patients a KT with any KDPI improved their chances of survival
suggesting that a pre-emtpive transplant is a feasible strategy for patients with ESRD. In this
case the only factor to consider is maximizing graft survival. High KDPI kidneys seemed to
have a marginal effect on 3-year patient survival post-KT vs remaining on the waitlist, event
though it does significantly increase the risk of death and graft failure post-KT. Meanwhile,
low KDPI kidneys seem to have the greatest effect on patients with mid tier EPTS. Bea
et al. had similar conclusions, however they did not consider graft survival as a competing
event to death [18]. For graft failure, in low EPTS patients the risk benefit was lower with
higher KDPI kidneys suggesting that waiting for a better kidney would reduce the chance
of re-transplantation, whereas high EPTS patients would still receive a positive risk benefit
with higher KDPI kidneys. In practice this would suggest that low EPTS patients can wait
longer in order to improve graft survival and patient survival , while high EPTS patients
would benefit by being transplanted as soon as possible while having almost no effect on
patient survival.
In the future, this CDS system could be simplified further by adding another model to
analyze the probability distribution of the competing events and reducing the final prediction
to an accept or decline decision. It was shown that for patients that died their risk of death
was greater than any other risk in the short term, suggesting that this pattern would be
highly indicative of a high risk patient that could potentially benefit from any organ offer,
while low risk patients seemed to have a higher chance of KT at all time points suggesting
they have time to wait until graft survival is maximized.
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5.2 IMPLICATIONS FOR CDS SYSTEMS IN PRODUCTION
CDS systems still have a ways to go before widespread adoption. Luckily, the attention
in this field is great with work being done by even the largest companies, such as Google1
and Microsoft2. An interesting example in kidney transplant is OmniLife, a Small Business
Innovation Research (SBIR) funded (among other private investment) startup working in
the transplant space with a unique forward thinking solution for kidney transplant offer and
patient management. During a successful SBIR phase I project, OmniLife proved the feasi-
bility of improving donor management and coordination using a streamlined communication
application, TXP Chat. The key TXP Chat innovation is in its user-focused design and
application specific awareness to the transplant continuum. TXP Chat replaces the slow,
point-to-point call centers reliant on phones, faxes and paper forms (Figure 1.1) with more
advanced technology enabling communication across institutional boundaries (Figure 5.1).
TXP Chat allowed clinicians to communicate more effectively and with higher user interface
satisfaction, thus facilitating more efficient decision making.
Figure 5.1: OmniLife Simplifies the complex communication network and allows rapid ex-
change of information at the time of offer. A clinical decision support system on their system
would be accessible by all parties involved on a transplant case.
In a proposed SBIR phase II research direction, TXP Chat will be enhanced with the
development of a clinical decision support (CDS) system called Ask Alan that will be capable
of delivering predictive insights at the time of offer from powerful machine learning models
(Figure 5.2). Ask Alans predictive capabilities will be improved upon by further integrating
1https://ai.google/healthcare/
2https://www.microsoft.com/en-us/research/research-area/medical-health-genomics/
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the system with powerful data sources inherent in the transplant professionals workflow,
such as the electronic medical record (EMR) (Figure 5.3).
Figure 5.2: The user interface for a clinical decision support system supporting multiple
clinical predictive models.
Figure 5.3: Integration with local EMR and Omnilife databases would allow for more gran-
ular and possibly accurate predictions.
The current opinion among clinicians in organ transplantation is that predictive models
trained with national datasets cannot ensure transportability to local environments [32].
This is a very valid argument and attempts have been made to alleviate this issue [33, 34].
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However, powerful local databases exist within every hospital and even in patient smart-
phones. In kidney transplantation, technology like TXP Chat represent a unique, secure
access point for both predictive models and local data sources, not only removing barriers
for researchers but also for hospitals and medical institutions who might not have the proper
software infrastructure to support CDS systems across institutional boundaries. Other re-
lated solutions exist such as doc.ai3 utilizing blockchain technology to democratize medical
research. In any case, for the majority of models published by researchers to have clinical
meaningfulness they need to demonstrate reproduciblity in local environments, and local
environments need to have the ability to implement and support the model in production.
Besides the infrastructure considerations necessary to support a system like this in produc-
tion, another area that should be explored is in the realm of Human Computer Interaction
(HCI). Representing complex predictions in a manner that can confidently influence clinical
decision making is not a trivial task [35]. While statistically one can ensure the accuracy of
a prediction, one cannot so easily ensure interpretability especially in a rapid paced clinical
environment where patient lives are at stake. Normally, to measure the effectiveness of a
new software feature a company can employ A/B testing, but Narayanan et al. found that
in machine learning these types of studies don’t lead to generalized conclusions about what
properties are most essential in certain contexts [35]. Therefore, more careful studies need
to be done with clinicians to generate guidelines as to what properties lead to increased
trust and usability, aside from performance. As noted in [36], ”designing an algorithm for
implementation in the clinic involves matter well beyond algorithmic performance” and they
conclude that interpretability is the first towards trust. In the context of kidney transplan-
tation, this work was able to show the clinical interpretability of predictions made by the
deep learning model and any attempt to use these predictions in clinical practice would likely
require similar interpretability with every organ offer.
3https://doc.ai/
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